The oligonucleotide therapeutic market is evolving rapidly, driven by breakthroughs in RNA-based medicines and the need for scalable, high-purity manufacturing solutions. At Entegris, we partner with innovators to enable targeted tissue delivery chemistries, overcome scale-up challenges, and meet complex CMC requirements.
In this issue, we explore critical topics shaping the future of RNA therapeutics, including:
- Thermal Stability in Oligonucleotide Synthesis – Why Phosphoramidite stability matters for process safety and quality.
- End-to-End Manufacturing Solutions – Strategies to enable large-scale oligonucleotide processing.
- Alternative Phosphitylating Reagents for Terminal Phosphate Oligonucleotides – Safer, more efficient approaches for complex chemistries.
- The Art of Phosphitylation – Understanding how Phosphoramidite selection can fine-tune synthetic oligo processes.
- Single-Use Solutions for Oligonucleotide Therapies – Reducing contamination risks for APIs in solution and advanced gene therapy manufacturing.
Join us as we share insights, best practices, and innovations designed to help you scale with confidence and deliver therapies that transform lives.
